In the abstract, titled, “Preliminary results of a Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors,” investigators continued to provide validation from early results of the single dose cohort of its Phase 1 clinical trial. The data presented include the pharmacokinetics and immune response observed in both cohorts in the ongoing Phase 1 trial for Decoy20. A single i.v. dose of Decoy20 disappeared from blood within 30-120 minutes and produced transient induction in plasma of over 50 cytokines and chemokines, many of which have been associated with stimulation of innate and/or adaptive immune responses. These findings are important components of the “pulse-prime” hypothesis for Decoy20’s anti-tumor effect.
The study also showed that despite the presence of multiple immune agonists associated with intact bacteria, the safety profile of Decoy20 was largely as expected for administration of purified lipopolysaccharide (LPS), based on previously published clinical experience. Adverse effects were generally tolerable and resolved with or without treatment within 90 minutes to 3 days.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things: our expectations and plans regarding our Phase 1 clinical trial of Decoy20, including the timing and design thereof; the anticipated effects of our product candidates, including Decoy20; the plans and objectives of management for future operations; our research and development activities and costs; the sufficiency of our cash and cash equivalents to fund our ongoing activities and our cash management strategy; and our assessment of financing options to support our corporate strategy. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; conditions and events that raise substantial doubt regarding our ability to continue as going concern; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption “Risk Factors” included in our Quarterly Report on Form 10-Q for the quarter ended
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IR
louie@coreir.com
Media:
shira@cuttlefishpr.com
917-280-2497
![](https://ml.globenewswire.com/media/ZGIwZWM4NGYtYjc3NS00Y2ZlLTgwYzMtODRmMmE0MDM2ZGUxLTEyMzM2MjI=/tiny/Indaptus-Therapeutics.png)
2024 GlobeNewswire, Inc., source